Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells as they affect functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells.
Request For Sample Report@ https://www.alliedmarketresearch.com/request-sample/3723
Impact of COVID-19 on Immune Checkpoint Inhibitors Market
- Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
Furthermore, the
virus has high potential of lethality in geriatric population. On March 11,
2020, the World Health Organization made an assessment that COVID-19 can be
characterized as pandemic. In addition, only a few vaccines that received
emergency approvals for COVID-19 prevention. Thus, social distancing is
observed as the most important measure to stop the spread of this disease. Furthermore,
to maintain social distancing, various countries across the world have adopted
nationwide lockdowns.
0 Comments